Pembrolizumab-Induced Thyroiditis and Colitis—Presentation and Resolution on Serial FDG PET/CT
- 21 September 2020
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (2) , e121-e122
Abstract
A 58-year-old man with previous melanoma of the left leg underwent whole-body 18F-FDG PET/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized—cessation of treatment often leads to resolution.Keywords
This publication has 7 references indexed in Scilit:
- Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse eventsImmunoTargets and Therapy, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 2017
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsThe Oncologist, 2016
- 18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and PrognosisAmerican Journal of Roentgenology, 2015
- Systematic review: colitis associated with anti‐CTLA‐4 therapyAlimentary Pharmacology & Therapeutics, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015